Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
IBIO - iBio Inc
-0.17(-10.30%)8:00:00 PM 5/12/2021
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics

Stock news

    iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021

    BRYAN, Texas, May 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 third quarter financial results before market open on Monday, May 17, 2021. iBio management will host a webcast and conference call at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Company’s web...

    Here's Why iBio Stock Surged Friday

    Shares of iBio (NYSEMKT: IBIO) climbed on Friday after the biotech announced plans to develop an intriguing second-generation vaccine candidate for COVID-19. By targeting the N protein, iBio hopes to develop a vaccine that will be highly effective against new coronavirus variants. "The N protein strategy of IBIO-202 is complementary to existing first-generation, S protein-directed vaccines and may be suitable as a more universal coronavirus vaccine," iBios' chief scientific officer, Martin Bre...

    IBIO Stock: The Covid-19 Vaccine News Sending iBio Soaring Today

    Ibio (NYSEAMERICAN:IBIO) stock is soaring higher on Friday after announcing a next-generation vaccine program to treat the novel coronavirus. Source: Shutterstock This new program has it developing IBIO-202 for the prevention of coronavirus. The candidate uses antigens derived from the spike protein fused with its own LicKM booster molecule. The positive news from that program today is the completion of IND-enabling toxicology studies. These studies found that there were no adverse effects at lo...

    iBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine Candidate

    iBio Inc (NYSE: IBIO) has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201 combines antigens derived from the spike protein ("S protein") fused with iBio's patented LicKM booster molecule It recently completed IND-enabling toxicology studies. No adverse effects at low or high doses were identified. The Company also reported on the developm...

    Why iBio Stock Soared Today

    Shares of iBio (NYSEMKT: IBIO) surged on Wednesday after the biologics manufacturer announced it had successfully resolved a multiyear lawsuit with Fraunhofer USA. The settlement confirmed iBio's ownership of key intellectual property related to its plant-based biopharmaceutical-production system. The agreement will also see iBio grant Fraunhofer USA a license to use its protein-manufacturing technology.

    iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement

    BRYAN, Texas, May 04, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. (“Fraunhofer USA”). The parties’ settlement confirms iBio’s ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the settlement, iBio granted Fraunhofer USA a fully paid-up license to use t...